Dr. Dmitri Simberg's lab focuses on developing innovative drug delivery systems using lipid nanoparticles for treating invasive glioblastoma, a highly aggressive brain tumor. The research aims to enhance the effectiveness of drug therapies by overcoming barriers in the brain and targeting tumor cells directly. By understanding the trafficking and formulation of lipid-based nanoparticles, the lab seeks to improve treatment outcomes for patients with this challenging disease.

Dr. Xiaoqi Liu's lab focuses on understanding and treating castration-resistant prostate cancer (CRPC). The research aims to identify new ways to combat the resistance that some prostate cancers develop against current therapies. By exploring various signaling pathways and potential biomarkers, the lab seeks to improve treatment options for patients who no longer respond to standard androgen signaling inhibitors.

Dr. Monga's lab at the University of Pittsburgh studies how the Wnt-Beta-catenin signaling pathway influences liver development and functions. Their research explores how this signaling regulates liver cell growth and the overall organization of liver cells in different zones. By understanding these processes, the team aims to uncover new insights that could inform treatments for liver diseases.

Dr. Hyunil Jo's lab at UCSF focuses on researching liver fibrosis, a severe condition that leads to liver failure. The lab is working on developing new drugs that target an enzyme called acid ceramidase, which has been shown to play a significant role in liver fibrosis. By creating potent inhibitors of this enzyme, they hope to provide effective treatments for patients suffering from chronic liver diseases, where current options are limited.

Dr. Yan Shu's laboratory at the University of Maryland Baltimore focuses on discovering new drugs to treat non-alcoholic steatohepatitis (NASH), a liver disease affecting many Americans. The lab studies how certain proteins and pathways in the liver contribute to the disease and uses innovative small molecules to improve liver health. Their research aims to develop and evaluate new compounds that could become the first effective treatments for NASH.

Dr. Robert Helsley's lab at the University of Kentucky focuses on understanding how problems with fat digestion in the liver can lead to serious health issues like metabolic dysfunction-associated steatotic liver disease (MASLD). Their research aims to explore the role of a specific enzyme involved in fat oxidation, which could help identify new ways to treat liver diseases. The lab uses advanced techniques in mouse models, cell cultures, and state-of-the-art genetic analysis to uncover the mechanisms behind liver fat accumulation and its effects on health.

Dr. Wanqing Liu's lab at Wayne State University focuses on understanding how heavy metals interact with our genes and how these interactions may contribute to nonalcoholic fatty liver disease (NAFLD). They investigate how metal exposure affects liver cells and the overall health of the liver, aiming to provide insights that could lead to new diagnostics and treatments for liver diseases. Their work combines advanced techniques in genomics and bioinformatics to analyze human liver tissues and patient data.

Dr. Michael Oertel's lab at the University of Pittsburgh focuses on understanding and improving liver health by studying cell competition, a process where certain cells outcompete others for space and resources. Their research aims to use this knowledge to develop new cell-based therapies that can help treat chronic liver diseases. By investigating how fetal liver cells behave differently compared to mature liver cells, the lab seeks to produce enhanced liver progenitor cells that can effectively regenerate damaged tissue.

The lab led by Adam Salmon at the University of Texas Health Science Center focuses on researching potential anti-aging therapies through the testing of small molecules in mice. By examining how these treatments can extend the lifespan and improve health conditions associated with aging, their goal is to find effective interventions that could eventually benefit human longevity. This work is part of a larger collaborative program that not only evaluates drug effects but also contributes essential data and tissues to the scientific community.

Dr. Zhipeng Lu's lab at the University of Southern California focuses on understanding how alternative splicing works and its implications for health and disease. They develop innovative methods to analyze RNA structures and their interactions with proteins, aiming to decode how these processes contribute to diseases like cancer and neurological disorders. The lab's work is particularly relevant for advancing precision medicine by targeting splicing mechanisms for therapeutic purposes.

Dr. Philip Lazarus's lab focuses on understanding how tobacco-related chemicals contribute to lung cancer, particularly through the metabolism of specific compounds called nitrosamines. They aim to identify genetic and phenotypic markers that can help predict lung cancer risk in smokers, using diverse cohort studies. This research could lead to new prevention strategies for lung cancer, particularly for high-risk populations.

Dr. Mark Gillespie's lab at the University of South Alabama focuses on understanding how lung cells respond to low oxygen levels and the role of mitochondrial DNA in lung inflammation. The research aims to uncover new mechanisms that regulate gene expression during hypoxia and explore how mitochondrial damage contributes to lung diseases. By studying these processes, the lab seeks to identify potential therapeutic targets for treating conditions like pulmonary hypertension and acute lung injury.

Dr. Alexander D. Mackerell's lab at the University of Maryland Baltimore studies the shapes and behaviors of biological macromolecules like proteins and RNA to understand how these aspects relate to their functions. By developing new computational methods and models, the lab aims to improve drug discovery processes, especially in relation to therapeutic targets for diseases like cancer and infectious diseases. The research combines techniques in biomolecular simulation and conformational analysis to explore complex biochemical interactions.

Dr. Rodney Kiplin Guy's lab focuses on improving the effectiveness of new antimalarial drugs called ATP4 inhibitors. The research aims to understand how these drugs work in combination with others and how to reduce the risk of malaria parasites developing resistance. By studying both laboratory and animal models, the lab seeks to find the best combinations of drugs that can treat malaria effectively while minimizing the chance that parasites will become resistant to treatment.

Dr. Kafait U Malik's lab focuses on understanding how hormones like estrogen and testosterone interact with specific enzymes in the brain, influencing blood pressure, especially in relation to sex differences. They utilize various advanced techniques to explore these interactions, aiming to identify new treatment strategies for hypertension and related health issues.

Dr. Eunsook Yu Lee's research lab investigates how manganese exposure can lead to neurological diseases, especially conditions that mimic Parkinson's disease. The lab studies a protein called Leucine-rich repeat kinase 2 (LRRK2), which is involved in various brain functions. By understanding how manganese affects this protein and microglia, the immune cells in the brain, the lab aims to find new treatments for manganese toxicity and related neurodegenerative disorders.

Dr. Somshuvra Mukhopadhyay's lab at the University of Texas at Austin focuses on understanding how manganese, an essential metal, can become toxic and lead to neurological diseases. The lab studies the mechanisms of manganese excretion and how it affects neurotoxicity, particularly in vulnerable populations like children. By exploring the relationship between manganese levels in the body and neurological health, the lab aims to find new therapeutic strategies for manganese-related disorders.

Dr. Aashish Manglik's lab at UCSF focuses on understanding how our sense of smell works. They study specific proteins called odorant receptors, which allow us to detect various smells. By analyzing the structure and function of these receptors, the lab aims to uncover the mechanisms of smell perception, which could lead to new treatments for smell-related disorders.

Dr. Eric W Schmidt's lab focuses on discovering new antibacterial drugs and understanding the chemical diversity found in nature, particularly from marine animals and their symbiotic bacteria. They aim to develop innovative compounds that can combat multidrug-resistant pathogens and enhance our understanding of pain signaling in the sensory nervous system. By exploring the unique chemistry of these organisms, the lab hopes to advance drug discovery technologies and improve therapeutic approaches for various diseases.

Dr. Hendrik Luesch's lab at the University of Florida focuses on discovering new anticancer drugs from marine cyanobacteria, which are special microorganisms that produce unique chemical compounds. By studying these organisms, the team aims to find and develop innovative therapies that can effectively target cancer, particularly drug-resistant forms. Their research combines ecology, genomics, and synthetic chemistry to unlock the therapeutic potential hidden in marine biodiversity.